Search

Displaying all 6 results
DrugBest match

Galcanezumab

go.drugbank.com/drugs/DB14042
ApprovedInvestigational

Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CG...

  1. Indication

    Episodic Cluster Headache

    go.drugbank.com/conditions/DBCOND0029864
    Drugs: Galcanezumab
  2. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment

  3. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] were the only CGRP antagonists that possessed oral bioavailability[A189207] until the approval of [atogepant] in 2021.

  4. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022.

  5. Indication

    Migraine

    go.drugbank.com/conditions/DBCOND0017962
    Drugs: Acetaminophen · Acetylsalicylic acid · Almotriptan · Amitriptyline · Atenolol · Atogepant +34 more